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Background/Purpose: Keratoconus is the most common primary corneal ectatic disease and has consid-
erable importance in public health. Corneal collagen crosslinking (CXL) is a procedure to mitigate pro-
gression of keratoconus and reduce demand for corneal transplantation. The aim of this study was to
evaluate the effect of CXL on corneal topographic and uncorrected distance visual acuity (UDVA) by
Oculus Pentacam in the 15e30-year-old population.
Methods: In this descriptiveeanalytic study, we enrolled 38 eyes of 27 patients suffering from pro-
gressive keratoconus who were candidates for CXL. UDVA and the anterior and posterior corneal cur-
vatures assessed prior to and 12 months after CXL. Data were analyzed by the paired t test and p < 0.05
was considered signiﬁcant.
Results: One year after the CXL, mean UDVA signiﬁcantly improved 0.1 ± 0.25 logarithm of the minimal
angle of resolution (p ¼ 0.012). Changes for steep keratometry values, ﬂat keratometry, and mean
keratometry on the anterior corneal surface were statistically signiﬁcant (all p < 0.005). However, the
difference observed in maximum keratometry and astigmatism was not signiﬁcant (p ¼ 0.421 and
p ¼ 0.745, respectively). After 12 months, all four keratometry values on the posterior corneal surface had
increased signiﬁcantly (p< 0.005), while no signiﬁcant change observed in astigmatism (p ¼ 0.303).
Conclusion: Corneal collagen crosslinking has been revealed as an effective and minimally invasive
intervention for the treatment of progressive keratoconus that can improve UDVA.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Keratoconus is a bilateral noninﬂammatory disease. One of its
characteristics is reduction of biomechanical strength of cornea and
stromal thinning, which gradually decreases corneal thickness and
induces irregular astigmatism, myopia, corneal scaring, and
reduction of visual acuity.1 The incidence and prevalence of kera-
toconus are 50e230 and 54.4 per 100,000 in the general popula-
tion, respectively.2,3 It usually starts at the age of puberty and
progresses until the 3rde4th decades of life. The most severe stage
of the disease occurs at age 20e40 years.1,4 For early stages ofhave no competing interests.
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iety of Taiwan. Published by Elsevikeratoconus, one would use spectacles and contact lenses though
the progression of the disease can lead to irregular astigmatism or
corneal scaring, leaving no option other than corneal trans-
plantation in about 20% of patients.5 Corneal transplantation is an
expensive procedure with many complications such as high astig-
matism and graft rejection; hence, seeking for a way to halt this
progressive disease seems to be of crucial importance.6e8 For more
than a decade, corneal crosslinking (CXL) with riboﬂavin (vitamin
B2) and UV-A has been considered as the only method for
improving corneal biomechanical power.9 UV-A and riboﬂavin in-
crease the connections of collagen ﬁbers in cornea, which would
stabilize the corneal biomechanical indices.10,11 In this study, we
sought to assess the efﬁcacy of riboﬂavin UV-A light-induced
crosslinking in stopping the progression of keratoconus and to
compare the anterior and posterior corneal curvatures and uncor-
rected distance visual acuity (UDVA) prior to and 1 year afterer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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whether this procedure can reduce the need for corneal
transplantation.
2. Methods
In this prospective clinical trial, we enrolled 38 eyes of 27 pa-
tients suffering from keratoconus whowere candidates for CXL and
were eligible for this surgery. The inclusion criteria were: patients
with mild to moderate keratoconus; maximum keratometry value
(K reading) < 60 diopter (D); minimal corneal thickness > 400 mm;
and age between 15 years and 30 years. This clinical trial was
conducted in 2015 and 2016. Patients were randomly selected from
thosewhowere referred to an eye hospital and had the diagnosis of
progressive keratoconus. Progressive keratoconus was deﬁned as
one or more of the following changes over a period of 24 months:
an increase of 1.00 D or more in the steepest keratometry (Ks)
measurement; an increase of 1.00 D or more in manifest cylinder;
and an increase of 0.50 D or more in manifest refraction spherical
equivalent. Patients with the following criteria were excluded from
the study: history of herpetic keratitis; history of previous eye
surgery; severe dry eye; corneal infection; history of autoimmune
disorders; and usage of hard contact lens for 1 month prior to the
study.
The sample size was calculated based on Za ¼ 1.96, Zß ¼ 0.84,
Sd ¼ 4.4, and Dm ¼ 2 (D); ﬁnally 38 eyes were included in the study.
The protocol was described to all the participants and informed
consent was obtained. Nonconsenting individuals were excluded
from the study. We also described the necessity of this surgery and
efﬁcacy of CXL in halting the disease progression to the partici-
pants. The study protocol was approved by the ethical committee of
Iran University of Medical Sciences (IUMS), Tehran, Iran. All eyes
had a complete ophthalmological evaluation, including kera-
tometry, UDVAmeasurements, slit-lamp biomicroscopy (under low
illumination to avoid reﬂex tearing), and Rotating Scheimpﬂug
topography (Pentacam HR; Oculus Optikger€ate GmbH, Wetzlar,
Germany) prior to and 1 year after the CXL. The UDVAwas recorded
as Snellen value at the initial consultation and 12 months post-
operatively and converted to logarithm of the minimal angle of
resolution (logMAR) for statistical analyses. Topography measure-
ments were obtained using a rotating Scheimpﬂug camera (Pen-
tacam, Oculus Optikger€ate GmbH). The Scheimpﬂug system
generates a three-dimensional model of the cornea and anterior
segment that can evaluate the severity of keratoconus and to
evaluate the progression or regression rates using these indices.12,13
Topographic data were obtained preoperatively and 12 months
postoperatively. Maximum K values (Kmax), mean K values (Kmean),
ﬂat K values (Kf), and steep K values (Ks), as well as corneal astig-
matism were recorded from the topography data generated by the
Scheimpﬂug system.
Surgical technique was as follows. After local anesthesia was
administered with tetracaine solution 1% (Sina Darou, Tehran, Iran)
under sterile condition, the corneal epithelium was removed me-
chanically. Then, the cornea was impregnated with standard
isotonic riboﬂavin solution 0.1% (Collagex; LightMed, San Clemente,
CA, USA) every 5 minutes for 30 minutes, followed by UV-A irra-
diation at 5 cm for 30minutes. After 1 hour of surgery, ciproﬂoxacin
0.3% eye drops (Sina Darou, Tehran, Iran) were used and a bandage
lens was placed on the cornea. Then, betamethasone 0.1% (Sina
Darou) and ciproﬂoxacin 0.3% (Sina Darou) were applied four times
a day for 1 week. After this, the contact lens was removed and
ﬂuorometholone 0.1% eye drops (Sina Darou) were applied three
times a day for 3 weeks. All patients' clinical assessments were
performed by a single optometrist. One year after CXL, post-
operative examinations were carried out in the same way as thepreoperative examinations: slit lamp examination; UDVA; refrac-
tion; and corneal topography with Pentacam topographer (Oculus
Optikger€ate GmbH).
Statistical analysis was performed using SPSS 19.0 (IBM,
Armonk, NY, USA) software. The paired t test was used to check the
signiﬁcance of the difference between two dependent groups in
every continuous variable. Statistical signiﬁcance was assessed at
0.05 probability level and p < 0.05 was considered signiﬁcant. All
the values are presented as mean ± standard error of the mean or n
(%).
3. Results
This was a prospective interventional study that included 38
eyes of 27 patients. The mean age of patients was 22.5 years (range,
15e30 years) and 55.55% of them were male. At slit-lamp exami-
nation performed 12 months after CXL, all the eyes were cleared.
There were no serious complications such as infection or corneal
scar. The results indicated a signiﬁcant improvement in UDVA
(0.10 ± 0.25 logMAR; p ¼ 0.012). In addition, changes for Ks
(0.75 ± 1.09; p< 0.005), Kf (0.79 ± 1.23; p< 0.005), and Kmean
(0.79 ± 1.10; p< 0.005) in the anterior corneal surface were sig-
niﬁcant. The maximum keratometry (0.21 ± 1.65; p ¼ 0.421) and
anterior surface astigmatism (0.04 ± 0.84; p ¼ 0.745) showed no
signiﬁcant changes. One year after CXL, curvatures of the posterior
corneal surface signiﬁcantly increased, but the astigmatism level
showed no signiﬁcant changes (0.03 ± 0.21; p ¼ 0.303). Changes in
Ks, Kf, Kmean, and Kmax of the posterior corneal surface were:
0.12 ± 0.18D, 0.14 ± 0.16 D, 0.12 ± 0.12 D, and 0.24 ± 0.19 D
(p< 0.005), respectively. The pre-CXL and 1-year postoperative
data in patients with progressive keratoconus, including the Pen-
tacam results and the UDVA are shown in Table 1. Also, results of
Scheimpﬂug topographic measurements in a typical patient are
presented in Table 2.
4. Discussion
Corneal CXL is a promising new treatment for keratoconus and
corneal ectasia.7,11 It has been repeatedly demonstrated to be suc-
cessful in stabilizing progressive corneal ectatic disorders with a
good safety proﬁle. In CXL, the interaction of UV-A (365 nm) and
riboﬂavin leads to crosslinkingwithin the collagen and intracellular
matrix of the stroma, most predominantly in the anterior 300 mm,
resulting in strengthening of the cornea.8,10 In many cases, more-
over, CXL improves the patient's visual, refractive, and topographic
outcomes with few reported complications.12,13 Therefore CXL is
probably the only true treatment for corneal ectasia that directly
addresses the disease pathology and potentially avoids the need for
corneal transplantation.
Various studies have been conducted on the effect of this
method as an intervention that can be effective in controlling
progressive keratoconus; hence this study aimed to investigate its
effectiveness by assessing corneal curvature changes and UDVA.
Furthermore, the results of this study are showing signiﬁcant
changes in UDVA, steep, ﬂat, and mean of corneal front surface
curvatures and suggest that keratoconus did not only progress in
the study population but also improved (Table 1). These ﬁndings
were consistent with several previous studies.13e15 In addition,
Kmax represented stability in keratoconus level. However, the dif-
ference in the values may be due to sample size, patients' age,
follow-up periods, keratoconus intensity, and the location of cone.
Steinberg and colleagues16 showed changes of the anterior and
posterior corneal curvatures 2 years after the CXL for progressive
keratoconus. They reported that the mean of the ﬂat and steep
curvatures in the anterior corneal surface after 2 years the CXL,
Table 1
Mean distribution and standard deviation (SD) of the variables prior to and 12 months after CXL.







Uncorrected distance visual acuity (logMAR) 38 0.56 ± 0.51 0.45 ± 0.42 0.10 ± 0.25 0.012
Steep keratometry of anterior corneal surface (D) 38 47.35 ± 3.22 46.60 ± 3.06 0.75 ± 1.09 <0.005
Flat keratometry of anterior corneal surface (D) 38 44.22 ± 2.70 43.42 ± 2.82 0.79 ± 1.23 <0.005
Mean keratometry of anterior corneal surface (D) 38 45.73 ± 2.85 44.94 ± 2.82 0.79 ± 1.10 <0.005
Maximum keratometry of anterior corneal surface (D) 38 50.58 ± 3.75 50.36 ± 4.29 0.21 ± 1.65 0.421
Astigmatism of anterior corneal surface (D) 38 3.13 ± 1.58 3.18 ± 1.68 0.04 ± 0.84 0.745
Steep keratometry of posterior corneal surface (D) 38 7.08 ± 0.60 7.21 ± 0.65 0.12 ± 0.18 <0.005
Flat keratometry of posterior corneal surface (D) 38 6.37 ± 0.46 6.51 ± 0.51 0.14 ± 0.16 <0.005
Mean keratometry of posterior corneal surface (D) 38 6.37 ± 0.46 6.51 ± 0.51 0.12 ± 0.12 <0.005
Maximum keratometry of posterior corneal surface (D) 38 5.08 ± 0.52 4.84 ± 0.55 0.24 ± 0.19 <0.005
Astigmatism of posterior corneal surface (D) 38 0.72 ± 0.33 0.68 ± 0.40 0.03 ± 0.21 0.303
D ¼ diopters; logMAR ¼ logarithm of the minimal angle of resolution; UDVA ¼ uncorrected distance visual acuity.
Table 2
Results of Scheimpﬂug topography in a typical patient.
Parameter Preoperation 12 months
postoperation
Anterior surface of cornea
Steep keratometry (D) 47.7 46.90
Flat keratometry (D) 44.2 43.52
Mean keratometry (D) 45.95 45.2
Maximum keratometry (D) 50.61 50.38
Astigmatism (D) 3.50 3.42
Posterior surface of cornea
Steep keratometry (D) 7.1 7.25
Flat keratometry (D) 6.4 6.6
Mean keratometry (D) 6.75 6.9
Maximum keratometry (D) 7.3 7.4




D ¼ diopters; logMAR ¼ logarithm of the minimal angle of resolution.
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results showed similar facts: the ﬂat and steep curvatures on the
anterior corneal surface (0.79 D and 0.75 D, respectively) decreased
signiﬁcantly after the CXL (p< 0.005). In our study, sample size was
greater and also, the posterior corneal curvatures were evaluated.
A 2013 retrospective study by Toprak and Yildirim14 on 59 eyes
of 47 patients in Turkey illustrated the effect of CXL on Kmax and
UDVA. They reported thatmean UDVA and Kmax after CXL improved
signiﬁcantly (p< 0.001). In our study, the difference for UDVA was
signiﬁcant (p ¼ 0.012), but statistical analysis of the Kmax, showed
no signiﬁcant difference between prior to and 1 year after the
operation (p ¼ 0.421). Thus, although the two studies found an
improvement in UDVA after CXL, this insigniﬁcant difference for
Kmax can be attributed to the severity of keratoconus, location of the
cone, and age of patients. In Toprak and Yildirim's14 study, curva-
tures of the Ks, Kf, Kmean, and astigmatism value on the anterior or
posterior corneal surfaces were not evaluated. Legare et al15
assessed the safety and efﬁcacy the CXL on 39 eyes of 30 patients
and found that the UDVA from preoperative to 2 years post-
operative on mean 0.39 logMAR had improved (p< 0.001).
Although topographic indices remained stable and did not show
signiﬁcant changes. In our study, UDVA from before CXL to 1 year
after CXL was improved bymean 0.1 logMAR. Duration of follow-up
and how the UDVA was measured prior to and after the operation
may explain the difference in the mean UDVA in the two studies.
In a prospective case series study by Hashemi et al17 on 40 eyes
of 32 patients to evaluate CXL long-term results of patients with
progressive keratoconus, mean UDVA decreased from 0.67 ± 0.52
logMAR prior to surgery to 0.65 ± 0.51 logMAR 5 years aftersurgery. The average of Kmax and Kmean were reduced by 0.16 ± 2.20
D and 0.1 ± 1.69 D, respectively. Additionally, astigmatism level
changed from 3.14 ± 2.22 D to 2.49 ± 1.71 D. They concluded that
Kmean, Kmax, UDVA, and astigmatism did not change during the
5 years after surgery, while CXL is a safe operation that can stop
keratoconus progression and limit the need for keratoplasty. Our
ﬁndings support these ﬁndings where the mean UDVA varied from
0.56 ± 0.51 logMAR prior to surgery to 0.45 ± 0.42 logMAR after
surgery, while the variations of average Kmax and Kmean values
occurred within the ranges of 0.21 ± 0.65 D and 0.79 ± 0.10 D,
respectively. Change of astigmatism was from 3.13 ± 1.58 D to
3.18 ± 1.68 D. This insigniﬁcant difference can be attributed to the
study duration, keratoconus severity (bias caused by the inclusion
of Kmax value), location of cone and patients' age. However,
Hashemi et al17 did not study the steep and ﬂat curvatures of the
anterior corneal surface alone, or evaluate the curvatures and
astigmatism level of the posterior corneal surface. Hersh et al18 in
New Jersey reported changes in the UDVA and corneal topography
1 year after CXL in patients with progressive keratoconus and
corneal ectasia. The study was performed on 71 eyes and the dif-
ference in the mean UDVA between prior to and 12 months after
the CXL was as follows: the mean UDVA preoperative was
0.84 ± 0.34 logMAR and the mean UDVA postoperative was
0.77 ± 0.37 logMAR (p ¼ 0.04) and Kmax 1 year after the operation
was decreased in keratoconus patients; 2/0 ± 4/4 D (p ¼ 0.002). In
our study, comparison of UDVA and Kmax prior to and after CXL
showed that the difference for UDVA was statistically signiﬁcant
(p¼ 0.012), whereas that for Kmax was not (p¼ 0.421). Evaluation of
the posterior corneal surface curvatures was not done by Hersh
et al.18 In the current study, the assessment of posterior surfaces
showed that although curvatures signiﬁcantly increased, the in-
creases are not clinically signiﬁcant compared to the anterior sur-
face changes. This means that the CXL does not have a positive
effect on back surface curvatures, while the trivial impact of corneal
posterior compared to the anterior surface on eye refraction can be
the reason for not addressing the assessment of posterior surfaces
in other studies. The ﬁndings of this study can be used in devel-
oping new therapeutic modalities as well as new high-tech ap-
proaches such as brainecomputer interface techniques based on
visual interface.195. Conclusion
Our study showed a signiﬁcant improvement in topographic
corneal changes and UDVA results in patients with corneal ectasia
after the CXL. These results illustrate the efﬁcacy and usage of CXL
for keratoconus among patients with progressive keratoconus.
Based on the positive results obtained in various studies conducted
M. Safarzadeh et al. / Taiwan Journal of Ophthalmology 6 (2016) 127e130130on the efﬁcacy of this method, including the current study, CXL
presents an important strategy to halt the progress of keratoconus
and improve it, while it can also play an effective role in limiting
vision loss.
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